Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA.

Q2 Pharmacology, Toxicology and Pharmaceutics

Antiviral Chemistry and Chemotherapy Pub Date : 2018-01-01 DOI:10.1177/2040206618783924

R Anthony Vere Hodge

{"title":"Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA.","authors":"R Anthony Vere Hodge","doi":"10.1177/2040206618783924","DOIUrl":null,"url":null,"abstract":"<p><p>The 30th International Conference on Antiviral Research was held in Atlanta, GA, USA, from 21 to 25 May 2017. Each year, the International Society for Antiviral Research (ISAR) presents three major awards, this year to Mike Sofia (Elion award), David Chu (Holý award) and Maaike Everts (Prusoff award). Also this year, the inaugural ISAR Women in Science award lecture was presented by Priscilla Yang. For several years, International Conference on Antiviral Research (ICAR) has included at least one Keynote lecture, this year there were four. Although there are accounts of only these eight lectures, they reflect the diversity that is characteristic of ICAR - employment (academia, industry, public health), type of research (virus biology, potential antiviral targets, antiviral drugs, research organisation) and a range of viruses. For example, the viruses included were hepatitis C virus and hepatitis B virus (Mike Sofia), HIV and hepatitis B virus (David Chu), multiple antiviral projects (Maaike Everts), dengue (Priscilla Yang), rhinovirus C (Ann Palmenberg), polio (Mark Pallansch), HIV (Eric Hunter) and Zika virus (Pei-Yong Shi). This report ends with my personal comments giving examples in which this diversity can bring benefits. The 31st ICAR will be in Porto, Portugal, 11-15 June 2018.</p>","PeriodicalId":7960,"journal":{"name":"Antiviral Chemistry and Chemotherapy","volume":"26 ","pages":"2040206618783924"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2040206618783924","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral Chemistry and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2040206618783924","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

The 30th International Conference on Antiviral Research was held in Atlanta, GA, USA, from 21 to 25 May 2017. Each year, the International Society for Antiviral Research (ISAR) presents three major awards, this year to Mike Sofia (Elion award), David Chu (Holý award) and Maaike Everts (Prusoff award). Also this year, the inaugural ISAR Women in Science award lecture was presented by Priscilla Yang. For several years, International Conference on Antiviral Research (ICAR) has included at least one Keynote lecture, this year there were four. Although there are accounts of only these eight lectures, they reflect the diversity that is characteristic of ICAR - employment (academia, industry, public health), type of research (virus biology, potential antiviral targets, antiviral drugs, research organisation) and a range of viruses. For example, the viruses included were hepatitis C virus and hepatitis B virus (Mike Sofia), HIV and hepatitis B virus (David Chu), multiple antiviral projects (Maaike Everts), dengue (Priscilla Yang), rhinovirus C (Ann Palmenberg), polio (Mark Pallansch), HIV (Eric Hunter) and Zika virus (Pei-Yong Shi). This report ends with my personal comments giving examples in which this diversity can bring benefits. The 31st ICAR will be in Porto, Portugal, 11-15 June 2018.

Abstract Image

查看原文本刊更多论文

会议报告:在美国乔治亚州亚特兰大举行的第30届国际抗病毒研究会议。

第30届国际抗病毒研究会议于2017年5月21日至25日在美国佐治亚州亚特兰大举行。每年，国际抗病毒研究学会(ISAR)都会颁发三个主要奖项，今年是Mike Sofia (Elion奖)，David Chu (Holý奖)和Maaike Everts (Prusoff奖)。同样在今年，Priscilla Yang主持了首届ISAR女性科学奖讲座。几年来，国际抗病毒研究会议(ICAR)至少包括一个主题演讲，今年有四个。虽然只有这八个讲座，但它们反映了ICAR的多样性特征——就业(学术界、工业界、公共卫生)、研究类型(病毒生物学、潜在的抗病毒目标、抗病毒药物、研究组织)和一系列病毒。例如，包括丙型肝炎病毒和乙型肝炎病毒(Mike Sofia)、艾滋病毒和乙型肝炎病毒(David Chu)、多个抗病毒项目(Maaike Everts)、登革热(Priscilla Yang)、鼻病毒C (Ann Palmenberg)、脊髓灰质炎(Mark Pallansch)、艾滋病毒(Eric Hunter)和寨卡病毒(Pei-Yong Shi)。本报告以我个人的评论结束，举例说明这种多样性可以带来好处。第31届ICAR将于2018年6月11日至15日在葡萄牙波尔图举行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Antiviral Chemistry and Chemotherapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.20

自引率

0.00%

发文量

审稿时长

15 weeks

期刊介绍： Antiviral Chemistry & Chemotherapy publishes the results of original research concerned with the biochemistry, mode of action, chemistry, pharmacology and virology of antiviral compounds. Manuscripts dealing with molecular biology, animal models and vaccines are welcome. The journal also publishes reviews, pointers, short communications and correspondence.